GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valerio Therapeutics (XPAR:ALVIO) » Definitions » Valuation Rank

Valerio Therapeutics (XPAR:ALVIO) Valuation Rank


View and export this data going back to 2005. Start your Free Trial

What is Valerio Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Valerio Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Valerio Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Valerio Therapeutics (XPAR:ALVIO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valerio Therapeutics (XPAR:ALVIO) » Definitions » Valuation Rank
Comparable Companies
XPAR:ALNFL XPAR:PHXM XPAR:ALCOX XPAR:ALDVI XPAR:ALPAT XPAR:ALTHX XPAR:ALTME XPAR:ALMDP XPAR:ALACT XPAR:ALINT OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
C4X:Germany
Address
49 Boulevard du General, Martial Valin, Paris, FRA, 75015
Website
https://www.valeriotx.com
Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.